Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Oe, Denmark; Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark.
Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Oe, Denmark.
Eur J Pharmacol. 2017 Dec 5;816:154-160. doi: 10.1016/j.ejphar.2017.03.053. Epub 2017 Mar 25.
Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.
慢性肾脏病影响多达 13%的人群，与心血管疾病发生风险显著增加相关。其潜在原因之一是动脉粥样硬化的加速发展。这既归因于传统心血管危险因素的发生率增加，也归因于可能仅存在于慢性肾脏病患者中的危险因素。后者体现在这样一个观察结果中，即目前主要针对传统危险因素的治疗方法不足以预防慢性肾脏病患者的心血管疾病。本综述讨论了加速尿毒症动脉粥样硬化的机制，特别关注载脂蛋白（apo）B 和 M 的假定作用，它们在慢性肾脏病患者中可能尤为重要。
